Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aldeyra The

ALDX
Current price
6.49 USD -0.01 USD (-0.15%)
Last closed 5.71 USD
ISIN US01438T1060
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 301 320 960 USD
Yield for 12 month +88.66 %
1Y
3Y
5Y
10Y
15Y
ALDX
21.11.2021 - 28.11.2021

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. Address: 131 Hartwell Avenue, Lexington, MA, United States, 02421

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.00 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-262 780 USD

Last Year

-258 707 USD

Current Quarter

Last Quarter

-61 631 USD

Key Figures ALDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -49 385 308 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -23.45 %
PEG Ratio
Return On Equity TTM -43.05 %
Wall Street Target Price 10.00 USD
Revenue TTM
Book Value 1.43 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -0.75 USD
Diluted Eps TTM -0.75 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALDX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ALDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date
Consecutive Years
Consistent Years
Continuous Dividends

Stock Valuation ALDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.50
Price Book MRQ 3.54

Financials ALDX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALDX

For 52 weeks

2.71 USD 6.55 USD
50 Day MA 5.16 USD
Shares Short Prior Month 3 890 513
200 Day MA 4.45 USD
Short Ratio 6.19
Shares Short 3 413 074
Short Percent 6.90 %